



EVALUATION OF ANTIDIABETIC AND  
ANTIOXIDANT PROPERTIES AND METABOLITE  
PROFILING OF *MOMORDICA CHARANTIA* FRUIT  
USING METABOLOMICS APPROACH

BY

VIKNESWARI A/P PERUMAL

A thesis submitted in fulfilment of the requirement for the  
degree of Doctor of Philosophy in Pharmaceutical Chemistry

Kulliyyah of Pharmacy  
International Islamic University Malaysia

February 2018

## ABSTRACT

*Momordica charantia* Linn (Cucurbitaceae) has been widely commercialized based on traditional usage as an antidiabetic product. However, the scientific evidence of its antidiabetic activity is not sufficient. Hence, the major aims of this research were to evaluate the antidiabetic activity of *M. charantia* fruit through proton-nuclear magnetic resonance (<sup>1</sup>H-NMR) spectroscopy based metabolomics, to investigate its mechanism of action, to profile the identified antioxidants as antidiabetic agents through liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) based metabolomics, and to develop a validated regression model using fourier transform infra-red spectroscopy (FT-IR) based fingerprinting. Initially, the fruit was extracted by the solvent with different ethanol in water concentration (0, 20, 40, 60, 80, 100%, v/v). Then, the extracts were subjected to different *in vitro* assays. The 80% aqueous ethanolic extract possessing the highest *in vitro* bio-activity was chosen for further *in vivo* antidiabetic evaluation utilizing <sup>1</sup>H NMR based metabolomics approach. *In vitro* dipeptidyl peptidase-4 (DPP-IV) inhibitory and 3T3-L1-cell glucose uptake activities were also tested for the same extract to explain its mode of action in relation to the metabolomics results. LC-MS and GC-MS based metabolomics approaches were applied to profile the bioactive compounds present in the extract. Finally, a validated calibration model was developed using FT-IR based fingerprinting. The 80% ethanolic extract showed a high inhibitory activity on 1, 1-diphenyl-2 picrylhydrazyl (DPPH) radical and high ferric reducing antioxidant power, but failed to exhibit inhibitory activity against  $\alpha$ -glucosidase and xanthine oxidase enzymes. Thereby, the antidiabetic activity of this extract was further evaluated using streptozotocin obese-diabetic induced rats (STZ ob-db). The results showed that the administration of the 80% ethanolic extract at 300 mg/kg bw for 4 weeks significantly ( $P < 0.05$ ) reduced the blood glucose level and normalized the blood lipid profile of rats. However, the data obtained from the metabolomics showed that the metabolite profiles of the serum and urine of rats could not be fully normalized by the 80% ethanolic extract and metformin. The identified biomarkers in serum and urine were 2-hydroxybutyrate, leucine, adipate, alanine, acetate, succinate, 2-oxoglutarate, dimethylamine, creatine, creatinine, betaine, glucose, taurine, phenylacetyl glycine, allantoin and hippurate. Furthermore, it was found to ameliorate the energy metabolism through the improvement of 3T3-L1-cell glucose uptake and inhibition DPP-IV but not through the inhibition of  $\alpha$ -glucosidase and xanthine oxidase. This extract displayed strong antioxidant activities which further showed a positive correlation to antidiabetic activity. LC-MS and GC-MS based metabolomics approaches helped to identify several antioxidants in this extract such as ascorbic acid, margarolic acid, brevifolincarboxylic acid, quercetin 3-O-glycoside, kuguacin H, cucurbitacin E, 3-malonylmomordicin I, goyaglycoside G, gentiobiose, glucose, galactonic acid, palmitic acid, galactose, mannose, and fructose. Finally, the validated regression model based on the FT-IR based fingerprinting has been successfully developed for the first time through this study in regard to predict the antioxidant activities of the new set of the extracts of *M. charantia*. In conclusion, this study showed that the *M. charantia* fruit extract has a great potential to be efficaciously used in the management of diabetes.

## خلاصة البحث

ثمرة المومردিকা تشارانتينا من الفصيلة القرعية، يتم تسويقه بشكل واسع كمنتج لعلاج مرض السكر. ولكن الأدلة العلمية على نشاطه المضاد لداء السكر ليست كافية. لذلك، الهدف الرئيس لهذه الدراسة التحقق من فعليته لعلاج داء السكري باستخدام الميتابولوميات مطيافية الرنين النووي المغناطيس (H-1 NMR) لاكتشاف الية عمله، التعرف على مضادة الاكسدة التي تعمل مضادة لداء السكر باستخدام الميتابولوميات المعتمدة على طريقة قياس الطيف الكتلي-الاستشراب السائل (LC-MS) وطريقة قياس الطيف الكتلي-الاستشراب الغازي (GC-MS) وهدفت أيضا لتطوير نموذج الخدار باستخدام التبصيم المعتمد على تحويل فوربييه مادون الأحمر (FT-IR). تم استخلاص الثمار بنقعها في محاليل الإيثانول والماء المختلفة التركيز (0، 20، 40، 60، 80، 100%، v/v). تم اختبار المستخلصات وتقييم نشاط هذه المكونات في اختبارات خارج الجسم الحي (in vitro). بعد ذلك تم اختيار المستخلص 80% ذي النشاط الأعلى لاختبار تقييم النشاط المضاد لداء السكري داخل الجسم الحي باستخدام الميتابولوميات المعتمدة على ال H-NMR1. تم وضع المستخلصات في اختبارات تثبيط إنزيم دايبيبتيل بيتايديس-4 (DPP[IV]) واختبار أخذ خلايا T3-L13 للجلوكوز لشرح آلية تأثيرها مع نتائج الميتابولوميات. أما الميتابولوميات المعتمدة على ال LC-MS و GC-MS فقد استعملت لتوصيف المركبات النشطة بيولوجيا في المستخلصات. وأخيرا تم تطوير نموذج مثبت الصحة باستخدام التبصيم المعتمد على ال FT-IR أظهرت مستخلصات ال 80% من الإيثانول نشاطا تثبيطيا عاليا على جذور 1-دايفينيل-2 بيكريلهايدرازيل وكان لها قوة مضادة للأكسدة (AOX) في إرجاع الحديدك، ولكن لم تكن فعالة في تثبيط إنزيم ألفا-جلوكوسيديس (AGI) وإنزيم زانتين أوكسيديس. ولذلك تم تقييم النشاط المضاد لداء السكري لهذا المستخلص باستخدام الجرذان المصابة بالسكري بالتسمين وبمركب ستريتوزوتوسين. أظهرت النتائج أن إعطاء المستخلص بجرعة 300 مج/كج من وزن الجسم 4 أسابيع خفض مستويات السكر في الدم بشكل ملحوظ ( $P < 0.05$ ) وأعاد مستوى الدهون في دماء الجرذان إلى مستواها الطبيعي. لوحظ نفس الأثر مع عقار الميتفورمين والأتوفاستاتن.. أثبتت أن المستخلص حسن الطاقة، والأحماض الأمينية، والبيورين، والكرياتينين، والمرارة، وأيضا مكروبات القناة الهضمية. بالإضافة إلى أنه أصلح أيضا الطاقة من خلال تحسين خلايا T3-L13 للجلوكوز ومن خلال تثبيط إنزيم DPP-IV ولكن من خلال (AGI) تم إثبات أن لدى هذا المستخلص نشاطا (AOX) والذي يرتبط إيجابيا بالنشاط المضاد لداء السكري. تستنتج هذه الدراسة أن مستخلصات ثمرة المومردিকা تشارانتينا تعتبر علاجا واعدة لمرض السكري.

## **APPROVAL PAGE**

The thesis of Vikneswari a/p Perumal has been approved by the following:

---

Alfi Khatib  
Supervisor

---

Qamar Uddin Ahmed  
Co-supervisor

---

Bisha Fathamah Uzir  
Co-supervisor

---

Siti Zaiton Mat So'ad  
Internal Examiner

---

Amin Ismail  
External Examiner

---

Zhari Ismail  
External Examiner

---

Siti Aesah @ Naznin Muhammad  
Chairman

## DECLARATION

I hereby declare that this thesis is the result of my own investigations, except where otherwise stated. I also declare that it has not been previously or concurrently submitted as a whole for any other degrees at IIUM or other institutions.

Vikneswari A/P Perumal

Signature.....

Date.....

**INTERNATIONAL ISLAMIC UNIVERSITY MALAYSIA**

**DECLARATION OF COPYRIGHT AND AFFIRMATION OF  
FAIR USE OF UNPUBLISHED RESEARCH**

**EVALUATION OF ANTIDIABETIC AND ANTIOXIDANT  
PROPERTIES AND METABOLITE PROFILING OF  
*MOMORDICA CHARANTIA* FRUIT USING METABOLOMICS  
APPROACH**

I declare that the copyright holder of this thesis are jointly owned by the student and IIUM.

Copyright © 2017 Vikneswari A/P Perumal and International Islamic University Malaysia. All rights reserved.

No part of this unpublished research may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without prior written permission of the copyright holder except as provided below

1. Any material contained in or derived from this unpublished research may only be used by others in their writing with due acknowledgement.
2. IIUM or its library will have the right to make and transmit copies (print or electronic) for institutional and academic purpose.
3. The IIUM library will have the right to make, store in a retrieved system and supply copies of this unpublished research if requested by other universities and research libraries.

By signing this form, I acknowledged that I have read and understand the IIUM Intellectual Property Right and Commercialization policy.

Affirmed by Vikneswari A/P Perumal

.....  
Signature

.....  
Date

## DEDICATION

*To my beloved father Mr. Perumal, my dearest mother Late Mrs. Meenachee and my loving family*

## ACKNOWLEDGEMENTS

I am grateful to God, who best owed me the strength and inspiration and also not forget his blessing of excellent health during the process of completing my project. I also would like to profound my appreciation and gratitude to all my supervisory committee. First and foremost, my gratitude goes to my supervisor Associate Professor Dr Alfi Khatib, whose encouragement throughout the research project. His knowledge, skill and commitment towards the project and student have made this work completed on time successfully. In addition, my special note of gratitude also goes to both Associate Professor Dr Qamar Uddin Ahmed and Assistant Professor Dr Bisha Fathamah Uzir for their constant guidance and extremely valuable advice and crucial contribution in this research project. A note of thanks should also go to technical staff at Kulliyah of Pharmacy, Br. Razif, Br. Najib, Br. Izahar and Sis. Azura who has given technical support and assistance.

Lastly, I would like have extended my sincere gratitude to my dearest family member and my supportive friend Miss Suganya Murugesu who deserve recognition for their tremendous encouragement, support, patience and prayers throughout my candidature. I dedicated my thesis to all of them.



# TABLE OF CONTENTS

Abstract .....	ii
Abstract in Arabic .....	iii
Approval Page .....	iv
Declaration .....	v
Copyright Page .....	vi
Acknowledgements .....	vii
List of Tables .....	xiii
List of Figures .....	xv
<b>CHAPTER ONE: INTRODUCTION .....</b>	<b>1</b>
1.1 Background of the Study .....	1
1.2 Problem Statements .....	5
1.3 Significance of the Study .....	6
1.4 Research Hypothesis .....	7
1.5 Research Objectives .....	7
<b>CHAPTER TWO: LITERATURE REVIEW .....</b>	<b>8</b>
2.1 Diabetes Mellitus .....	8
2.1.1 Definition .....	8
2.1.2 Classification and Etiology .....	9
2.1.2.1 Type 1 Diabetes Mellitus .....	9
2.1.2.2 Type 2 Diabetes Mellitus .....	10
2.1.3 Pathogenesis of Type 2 Diabetes .....	10
2.1.4 Oxidative Stress and Diabetes Mellitus .....	11
2.1.5 Diagnosis of Diabetes .....	13
2.1.6 Treatment of Diabetes .....	14
2.1.6.1 Treatment of DM by Insulin Injection .....	14
2.1.6.2 Treatment of DM by Improving Insulin Secretion .....	15
2.1.6.3 Treatment of DM via $\alpha$ -Glucosidase Inhibition .....	15
2.1.6.4 Treatment of DM via Dipeptidyl Peptidase-IV Inhibition .....	18
2.1.6.5 Treatment of DM by Improvement of Insulin Signaling to Glut-4 .....	22
2.1.6.6 Treatment of Diabetes using Herbs .....	23
2.2 Botanical Aspect .....	25
2.2.1 Characteristic .....	25
2.2.2 Varieties of <i>M.charantia</i> .....	26
2.3 Pharmacological properties of <i>M. charantia</i> .....	27
2.3.1 Antidiabetic Activity .....	27
2.3.2 Antiobesity Activity .....	31
2.3.3 Antimicrobial Activity .....	31
2.3.4 Anticarcinogenic Activity .....	32
2.3.5 Antioxidant Activity .....	32
2.3.6 Side Effect of <i>M.charantia</i> Fruit .....	35
2.4 Testing Related to Antioxidant .....	35

2.4.1 Ferric Reducing Antioxidant Power Assay .....	35
2.4.2 1,1-diphenyl-2 Picrylhydrazyl Antioxidant Assay.....	36
2.5 Bioactive Compounds in <i>M. charantia</i> .....	36
2.5.1 Charantin.....	39
2.5.2 Polypeptide-P .....	39
2.5.3 Vicine .....	40
2.5.4 Other Compounds Present in <i>M. charantia</i> .....	40
2.6 Metabolomics .....	43
2.6.1 NMR- based Metabolomics .....	45
2.6.2 GC-MS- based Metabolomics.....	46
2.6.3 LC-MS- based Metabolomics .....	47
2.6.4 FTIR- based Metabolomics.....	47
<b>CHAPTER THREE: MATERIALS AND METHODS .....</b>	<b>49</b>
3.1 Chemicals and Reagents .....	49
3.2 Apparatus .....	50
3.3 Plant Material .....	50
3.4 External Plant Material .....	51
3.5 Sample Extraction.....	51
3.6 <i>In vitro</i> Antidiabetic Activities .....	52
3.6.1 Assay for $\alpha$ -Glucosidase Inhibitory Activity .....	52
3.6.2 2-NBDG Uptake in 3T3-L1 Cells Assay .....	53
3.6.2.1 Cell Culture.....	53
3.6.2.2 Cell Viability Assay.....	54
3.6.2.3 3T3-L1 Preadipocyte Differentiation .....	54
3.6.2.4 2-NBDG Uptake in 3T3-L1 Cells .....	55
3.6.3 Dipeptidyl Peptidase-IV Inhibitory Assay .....	55
3.7 <i>In vitro</i> Antioxidant Activities.....	56
3.7.1 Xanthine Oxidase Inhibitory Activity .....	57
3.7.2 DPPH Radical Scavenging Activity.....	57
3.7.3 FRAP Activity.....	58
3.8 Effect of <i>M. charantia</i> Fruit Extract on Streptozotocin Obese- Diabetic Induced Rats.....	59
3.8.1 Preparation and Acclimatization of Rats.....	59
3.8.2 Inducing of Diabetic Rats.....	59
3.8.3 Treatment of STZ-OB-DB Induced Rats .....	60
3.8.4 Collection and Preparation of Urine and Serum .....	62
3.8.5 Biochemical Parameters.....	62
3.8.6 Acquisition of <sup>1</sup> H-NMR Spectra of Urine and Serum .....	63
3.9 Instrumental Analysis of <i>M. charantia</i> Fruit Extracts.....	64
3.9.1 Q-TOF LC-MS.....	64
3.9.2 GC-MS .....	65
3.9.2.1 Derivatization Procedure .....	65
3.9.2.2 GC-MS based Metabolomics.....	66
3.9.2.3 Quantification of Bioactive Compounds by GC-MS .....	67
3.9.2.4 Synergism Effect of Suspected Bioactive Compounds ....	69
3.9.3 FTIR-ATR Fingerprinting .....	69
3.10 Statistical Analysis .....	70

<b>CHAPTER FOUR: RESULTS AND DISCUSSIONS.....</b>	<b>72</b>
4.1 Screening of Aqueous Ethanolic Extracts <i>M. charantia</i> Fruit .....	72
4.1.1 Yield of Extractions .....	72
4.1.2 Alpha glucosidase inhibitory activity.....	73
4.1.3 Antioxidant activity.....	73
4.1.4 Discussion .....	77
4.2 Antidiabetic Activity of <i>M. charantia</i> Fruit Using Metabolomics Approach .....	79
4.2.1 Short Term Multiple Dose Effect of <i>M. charantia</i> Fruit Extract on Blood Glucose Levels of STZ Ob-Db Rats .....	79
4.2.2 Effect of <i>M. charantia</i> Fruit Extract on STZ Ob-Db Rats rats during 4 weeks treatment.....	82
4.2.2.1 Body Characteristic of Rats.....	82
4.2.2.2 Plasma Glucose Level .....	84
4.2.2.3 Biochemical Analysis and Fasting Serum Insulin.....	87
4.2.3 Visual Inspection of <sup>1</sup> H-NMR and Assignment of Serum And Urine Metabolites.....	89
4.2.4 Multivariate Data Analysis of Serum and Urine Metabolites.....	93
4.2.5 2-NBDG Uptake in 3T3-L1 Cells Assay .....	105
4.2.5.1 Cell Viability .....	105
4.2.5.2 2-NBDG uptake in 3T3-L1 Adipocytes .....	107
4.2.6 DPP(IV) Inhibitory Assay.....	109
4.2.7 Discussion .....	110
4.2.7.1 Energy Metabolism.....	113
4.2.7.2 Amino Acid Metabolism .....	117
4.2.7.3 Purine Metabolism.....	118
4.2.7.4 Creatine Metabolism.....	119
4.2.7.5 Bile Acid Metabolism.....	119
4.2.7.6 Metabolites from Gut Microflora .....	120
4.3 Metabolite Profiling of <i>M. charantia</i> Fruits based Metabolomics Approach. ....	121
4.3.1 LCMS-based Metabolites Profiling .....	121
4.3.2 GCMS-based Metabolites Profiling.....	131
4.3.3 Discussion .....	140
4.4 Fingerprinting of <i>M. charantia</i> Fruit Extracts Using FT-IR based Metabolomics. ....	143
4.4.1 FT-IR Spectrum Assignment .....	143
4.4.2 Multivariate Data Analysis .....	146
4.4.3 Validity of the Calibration Model.....	149
4.4.3 Discussion .....	152
 <b>CHAPTER FIVE: CONCLUSION AND RECOMMENDATIONS .....</b>	 <b>158</b>
 <b>REFERENCES.....</b>	 <b>162</b>
 <b>APPENDIX I: <sup>1</sup>H-NMR CHEMICAL SHIFTS OF METABOLITES IN THE SERUM AND URINE .....</b>	 <b>191</b>
<b>APPENDIX II: SPECTRUM OF LCMS IDENTIFIED COMPOUNDS .....</b>	<b>196</b>

<b>APPENDIX III: FRAGMENTAION PATHWAY OF IDENTIFIED ANTIOXIDANT FROM Q-TOF-LCMS .....</b>	<b>204</b>
<b>APPENDIX IV: TABLES .....</b>	<b>261</b>
<b>APPENDIX V: GRAPH OF DPPH AND ALPHA GLUCOSIDASE INHIBITON AT 50% OF CONCENTRATION.....</b>	<b>268</b>
<b>APPENDIX VI: GCMS SPECTRA .....</b>	<b>274</b>
<b>APPENDIX VII: DPPH AND FRAP OF ISOLATED COMPOUNDS .....</b>	<b>280</b>
<b>APPENDIX VIII:THE SOURCE OF EXTERNAL SAMPLE FOR FTIR VALIDATION.....</b>	<b>282</b>
<b>APPENDIX IX: REFERNCES FOR SPECTRA IN FIGURE 4.3.....</b>	<b>283</b>
<b>APPENDIX X: REFERENCES FOR LCMS POSITIVE AND NEGATIVE IONIZATION.....</b>	<b>285</b>
<b>APPENDIX XI: <i>Momordica charantia</i> FARM AT PERAK .....</b>	<b>288</b>
<b>APPENDIX XII: SOP FOR QUANTIFICATION OF METABOLITES IN SAMPLE USING GCMS.....</b>	<b>289</b>
<b>APPENDIX XIII:PUBLICATIONS.....</b>	<b>294</b>
<b>APPENDIX XIV:CONFERENCES AND AWARDS.....</b>	<b>295</b>

## LIST OF TABLES

<u>Table No.</u>		<u>Page No.</u>
4.1	Yield of Extractions of Different Aqueous Ethanolic extracts of <i>M. charantia</i> Fruit	74
4.2	Alpha-glucosidase Inhibitory Activity of Different Aqueous Ethanolic Extracts of <i>M. charantia</i> Fruit	75
4.3	Comparison of FRAP Values and DPPH Radical Scavenging Activity of Different Aqueous Ethanolic Extracts of <i>M. charantia</i> Fruit	75
4.4	Xanthine Oxidase Inhibitory Activity of Different Aqueous Ethanolic Extracts of <i>M. charantia</i> Fruit	76
4.5	Comparison of Body's Characteristic of Different Groups of Rats at Baseline (Week 15), and Final Period Time (Week 18)	83
4.6	Plasma Blood Glucose Levels of Rats of Different Groups	85
4.7	Lipid Profiles of Normal, Obese-Diabetic, 300 mg/kg b.w of <i>M. charantia</i> , and 35 mg/kg b.w of Atorvastatin-Treated Rats at Baseline (week 15) and Final Time Period (week 18).	87
4.8	Metabolites Quantification of the Serum by <sup>1</sup> H-NMR at the Final Period.	98
4.9	Summary of Metabolites Changes in the Serum at Final Period.	99
4.10	Metabolites Quantification of the Urine by <sup>1</sup> H-NMR at Final Period.	101
4.11	Summary of Metabolites Changes in Urine at Final Period.	102
4.12	Tentative Antioxidants in Aqueous Ethanolic Extracts of <i>M. charantia</i> Fruit based on the MS <sup>2</sup> Fragmentation using Negative Ionization.	128
4.13	Tentative Antioxidants in Aqueous Ethanolic Extracts of <i>M. charantia</i> Fruit based on the MS <sup>2</sup> Fragmentation using Positive Ionization.	129
4.14	Metabolites Identified in the Extracts of <i>M. charantia</i> Fruit based on NIST 2014 (Gaithersburg, MD, USA) Database.	135
4.15	DPPH and FRAP Antioxidant Analysis of Individual Analyte.	136

4.16	Calibration Curves, Detection Limits and Quantification Limits Measured by GC-MS.	137
4.17	FRAP (AAE $\mu\text{g}$ of ascorbic acid/g) Values of 80% Ethanolic Extract of <i>M. charantia</i> Fruit Spiked with Different Amount of Identified Individual Antioxidant.	139
4.18	The $\text{IC}_{50}$ (mg/mL) Values of DPPH Radical Scavenging Activity of Spiked 80% Ethanolic Extract of <i>M. charantia</i> Fruit Spiked with Different Amount of Identified Individual Antioxidant.	139
4.19	FTIR-ATR Spectra Peaks Assignment of <i>M. charantia</i> Ethanolic Extracts based on Pavia et al. (2008).	146
4.20	The Actual and Predicted Values of FRAP Value and DPPH Radical Scavenging Activity of 80% Ethanolic Extract of <i>M. charantia</i> Fruit from 10 Different Shops in Kuantan, Malaysia.	151

## LIST OF FIGURES

<u>Figure No.</u>		<u>Page No.</u>
2.1	Glucosidase Inhibitors-The Oral $\alpha$ -Glucosidase Inhibitors (Ghani, 2015)	17
2.2	Mechanism of Actions of Dipeptidyl Peptidase-IV Inhibitors (Chen et al., 2015).	20
2.3	Chemical Structures of Clinically Approved DPP-IV Inhibitors, Including Alogliptin, Anagliptin, Gemigliptin, Linagliptin, Saxagliptin, Sitagliptin, Teneligliptin, and Vildagliptin (Chemspider).	21
2.4	Chemical Structures of Clinically Approved Thiazolidinediones Class Drug Including Troglitazone, Rosiglitazone and Pioglitazone (Chemspider).	23
2.5	The <i>Momordica charantia</i> var. <i>Charantia</i> Fruit.	26
2.6	Isolated Compounds from <i>M. charantia</i> by Hu et al. (2013).	30
2.7	Antioxidants from <i>M. charantia</i> (Chemspider).	34
2.8	Structure of Major Antidiabetic Bioactive Compounds Present in <i>M. charantia</i> (Chemspider).	38
2.9	Chemical Structure of Some Bioactive Compounds Present in <i>M. charantia</i> (Chemspider).	42
2.10	Regression Model Calculated using Orthogonal-Partial Least Square to Correlate Chemical Profile of the Herbal Extract and Bioactivity (Roos et al., 2004).	44
3.1	Systemic Diagram of an Experimental Design of STZ Obese - Diabetic Induced Rat Model. Each Group Contains 5 Rats (n=5).	61
3.2	Flow Chart of Methodology	74
4.1	Multiple Dose Effect of 80% Ethanolic Extract of <i>M. charantia</i> Fruit (MC) on Blood Glucose Levels of STZ Ob-Db Rats at Day 1 of Week 15. Data Corresponds to Mean $\pm$ SD with n = 5. The Small Letters Represents a Significant Difference (P < 0.05) Among the Blood Samples from Different Treatments and Analyzed at the Same Treatment Time. The Capital Letters Represents a Significant Difference (P < 0.05) Among the Blood Samples from the Same Treatment but Analyzed at Different Treatment Times.	81

- 4.2 Serum Insulin of Rats at Baseline (Week 15) and Final (Week 18) Period. The Values Express in Mean  $\pm$  SEM with n =3. The Capital Letters Represents the Significant Difference of the Serum Insulin Level of Rats Between Baseline and a Final Period at P < 0.05. The Small Letters Represent the Significant Difference Between the Serum Insulin Level Among Different Group of Rats Within the Same Experimental Period at P < 0.05. 89
- 4.3 <sup>1</sup>H-NMR Spectra of Serum Obtained from the Normal Rats at the Final Period Time. The Signals are Assigned as (1) 2-Hydroxybutyrate ( $\delta$  0.88), (2) Leucine ( $\delta$  0.94), (3) Valine ( $\delta$  0.99, 1.04), (4) Ethanol ( $\delta$  1.18, 3.56), (5) Lactate ( $\delta$  1.32, 4.11), (6) Alanine ( $\delta$  1.48, 3.77), (7) Acetate ( $\delta$  1.91), (8) Glutamate ( $\delta$  2.05, 2.14, 2.36, 3.76), (9) Glutamine ( $\delta$  2.14, 2.45, 3.76), (10) Succinate ( $\delta$  2.41), (11) Creatine ( $\delta$  3.04, 3.94), (12) Choline Derivatives ( $\delta$  3.15 - 3.24), (13) Betaine ( $\delta$  3.26, 3.90), (14) Glucose ( $\delta$  3.20-3.94, 4.65, 5.24) and (15) Taurine ( $\delta$  3.44). 91
- 4.4 <sup>1</sup>H-NMR Spectra of Urine Obtained from the Rats at the Final Period Time. The Signals are Assigned as (1) 2-Hydroxybutyrate ( $\delta$  0.88), (2) Leucine ( $\delta$  0.93), (3) Adipate ( $\delta$  1.52, 2.18), (4) Acetate ( $\delta$  1.91), (5) N – Acetyl groups ( $\delta$  2.0 - 2.2), (6) Succinate ( $\delta$  2.41), (7) 2-Oxoglutarate ( $\delta$  2.45, 3.01), (8) Citrate ( $\delta$  2.55, 2.69), (9) Dimethylamine ( $\delta$  2.73), (10) Creatine ( $\delta$  3.04, 3.94), (11) Creatinine ( $\delta$  3.05, 4.06), (12) Betaine ( $\delta$  3.25, 3.90), (13) Taurine ( $\delta$  3.28, 3.44), (14) Glucose ( $\delta$  3.20-3.90, 4.65, 5.24), (15) N-Phenylacetyl glycine ( $\delta$  3.68, 3.76, 7.37), (16) Allantoin ( $\delta$  5.40, 6.04), (17) Urea ( $\delta$  5.79), and (18) Hippurate ( $\delta$  3.98, 7.55, 7.62, 7.68). 92
- 4.5 PLS-DA Score Plot Obtained using <sup>1</sup>H-NMR Spectra of the (a) Serum and (b) Urine from the Normal, STZ Ob-Db, Metformin, and *M. charantia* Extract Treated Rats at Final Time Period (Week 18). 96
- 4.6 Permutation Test for (A) Serum Where R<sup>2</sup>Y is 0.29 and Q<sup>2</sup>Y is -0.64 and (B) Urine where R<sup>2</sup>Y is 0.30 and Q<sup>2</sup>Y is -0.30. 97
- 4.7 The metabolic pathway alteration in the serum (a) and urine (b) of STZ ob-db rats. The normalized biomarkers are shown in blue. 104
- 4.8 The Cell Viability of (A) Rosiglitazone, and (B) *M. charantia*-Treated 3T3-L1 Cells. Data Presented in Mean  $\pm$  SD. ANOVA Showed a Significant Value if the Letter is Different at P < 0.05. 106
- 4.9 NBDG Glucose Uptake in D-The 2ifferentiated 3T3-L1 Cells in the Absence (0 nM) and Presence (100 nM) of Insulin at a Different Concentration of Extract (25–200  $\mu$ g/mL) and Positive Control Rosiglitazone (5–40 nM). Data Presented in Mean  $\pm$  SD. ANOVA Showed Significant if the Letters is Different at P < 0.05. 108



4.10	Percentage of Inhibition of Sitagliptin and 80% Ethanolic Extract of <i>M. charantia</i> Fruit on DPP (IV) at Assay Concentration 0.5 mg/mL.	109
4.11	DPP(IV) Inhibition of 80% Ethanolic Extract of <i>M. charantia</i> at Different Assay Concentrations.	110
4.12	Score Scatter Plot for OPLS Model of Different Extracts of <i>M. charantia</i> Fruit (0, 20, 40, 60, 80, 100% ethanolic extracts) Analyzed using LC-MS with Negative (a) and Positive (b) Ionization.	123
4.13	Permutation Test for OPLS Model of LC-MS with Negative (a). The Intercept of R <sup>2</sup> Y and Q <sup>2</sup> Y were 0.08 and -0.34, respectively. (b) Permutation test for OPLS model of LC-MS positive ionization. The intercept of R <sup>2</sup> Y and Q <sup>2</sup> Y were 0.11 and -0.40, respectively.	124
4.14	The Loading Scatter Plot of OPLS Model of the Extracts Analyzed Using LC-MS with Negative Ionization. The Identified Antioxidants are (1) Ascorbic acid, (2) Margarolic Acid, (3) Brevifolincarboxylic Acid, (4) Quercetin 3-O-Glycoside, (5) Kuguacin H and (6) Cucurbitacin E.	126
4.15	The Loading Scatter Plot of OPLS Model of the Extracts Analyzed using LC-MS with Positive Ionization. The Identified Antioxidants were (1) 3-Malonylmomordicin I, and (2) Goyaglycoside G.	127
4.16	The Chemical Structures of the Identified Antioxidants in <i>M. charantia</i> Fruit Extract Analyzed Using LC-MS-based Metabolomics.	130
4.17	Score Scatter Plot for OPLS Model of Different Extracts of <i>M. charantia</i> Fruit (0, 20, 40, 60, 80, 100% Aqueous Ethanolic Extracts) Analyzed Using GC-MS.	131
4.18	Permutation Test for OPLS Model of GC-MS Correlated to DPPH Radical Scavenging (a) and FRAP (b) Activities.	133
4.19	Column Loading Plot for OPLS Model of <i>M. charantia</i> Extracts Analyzed by GC-MS.	134
4.20	GC-MS Chromatogram of 80% of Ethanolic Extract of <i>M. charantia</i> . For Peak Number and Retention Time Refer to Table 4.13.	134
4.21	Representative FTIR Spectra of Different <i>M. charantia</i> Fruit Extracted Using Ethanol in Water 0 % (a), 20 % (b), 40 % (c), 60 % (d), 80 % (e), and 100 % (f)	145
4.22	Separation of Different Samples of <i>M. charantia</i> Fruit, Extracted using a Different Percentage of Ethanol in water (0, 20, 40, 60, 80, and 100 % v/v), in the Score Scatter Plot based on OPLS-DA/ The R <sup>2</sup> x [1] is 0.467 and is R <sup>2</sup> X0 [1] is 0.304.	147

- 4.23 The Line Loading Plots of Constructed Orthogonal Partial Least Squares Model based on the Orthogonal Partial Least Squares Discriminant Analysis Model. 148
- 4.24 (A) The Permutation Test Result of Samples in Group 1 (Extracts of Ethanol 0, 20, 40, and 60 % of *M. charantia* fruit). The Intercept of the Fraction of Total Sums Square is 0.0874 While the Intercept of the Predictive Ability of the Model is -0.372. (b) the Permutation Test Result of Samples in Group 2 (Extracts of Ethanol 80 % and 100 % of *M. charantia* Fruit). The Intercept of the Fraction of Total Sums Square is 0.0891 While the Intercept of the Predictive Ability of the Model is -0.362. 150

## LIST OF EQUATIONS

<u>Equation no.</u>	<u>Page no.</u>
Equation 3.1	51
Equation 3.2	53
Equation 3.3	54
Equation 3.4	56
Equation 3.5	57
Equation 3.6	58
Equation 3.7	68
Equation 3.8	68

## LIST OF ABBREVIATIONS

<sup>1</sup> H NMR	Proton Nuclear Magnetic Resonance Spectroscopy
A	Absorbance
AAE	Ascorbic Acid Equivalent
ACUC	Animal Care and Use Committee
AGEs	Advanced Glycated End Products
AI	Atherogenic Index
AMD	Aminopyrine-N-Demethylase
AMPK	Adenosine-5-Monophosphate Kinase
ANH	Aniline Hydroxylase
BMI	Body Mass Index
BW	Body Weight
cAMP	Cyclic Adenosine Monophosphate
CDO	Cysteine Dioxygenase
CMC	Carboxymethylcellulose
CPMG	Carr-Purcell-Meiboom-Gill
CSAD	Cysteine Sulfinic Acid Dehydrogenase
DM	Diabetes Mellitus
DMEM	Dulbecco's Modified Eagle Media
DMSO	Dimethyl Sulfoxide
DPP(IV)	Dipeptidyl Peptidase 4
DPPH	1,1-Diphenyl-2-Picrylhydrazine
ESI	Electrospray Ionization
FBS	Fetal Bovine Serum
FPG	Fasting Plasma Glucose
FRAP	Ferric Reducing Antioxidant Power
FTIR-ATR	Fourier Transform Infra-Red-Attenuated Total Reflectance
G6PD	Glucose-6-Phosphate –Dehydrogenase
GAD65	Glutamate Decarboxylase 65
GAPDH	Glyceraldehyde 3-Phosphate Dehydrogenase
GCMS	Gas Chromatography Mass Spectrometry
GDM	Gestational Diabetes Mellitus
GIP	Gastric Inhibition Polypeptide
GLP 1	Glucagon-Like Peptide 1
GPC	Glycerophosphocholine
GPR91	G protein–coupled receptor-91
GST	Glutathione S-Transferase
HbA1C	Haemoglobin A1C
HDL	High Density Lipoprotein
HFD	High Fat Diet
IA	Islet Autoimmunity
ICRACU	Integrated Centre for Research Animal Care and Use
ID	Inner Diameter
JOD	Juvenile Onset Diabetes
LDL	Low Density Lipoprotein
LOD	Limit of Detection

LOQ	Limit of Quantification
MSTFA	N-Methyl-N- (Trimethylsilyl) Trifluoroacetamide
MTT	3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide
MVDA	Multivariate Data Analysis
NDA <sup>+</sup>	Nicotinamide Adenine Dinucleotide
NFB	Nuclear Factor Beta
NIDDM	Non-Insulin Dependent Diabetes Mellitus
NIST	National Institute of Standards Technology
NMR	Nuclear Magnetic Resonance Spectroscopy
OB-DB	Obese-Diabetic
OGTT	Oral Glucose Tolerance Test
OPLS	Orthogonal Partial Least Square
PAG	N-Phenylcetylglycine
PBS	Phosphate Buffer Saline
PLE	Pressurized Liquid Extraction
PLS-DA	Partial Least Square Discriminant Analysis
PNPG	<i>p</i> -Nitrophenyl- $\alpha$ -D-Gluucopyronase
PPHG	Post Prandial Hyper Glycemia
PW	Pulse Width
RAPD	Random Amplified Polymorphic DNA
RAGEs	Receptor Advanced Glycated End Products
RAS	Renin-Angiotensin System
RD	Relaxation Delay
RIN	Rat Insulinoma
SD	Standard Deviation
SD	Standard Deviation
SEM	Standard Error Mean
STZ	Animal Care and Use Committee
STZ	Streptozotocin
STZ-OBDB	Streptozotocin-Obese Diabetic
T2	Transverse Relaxation Time
TAGE	Toxic Advanced Glycated End Products
TCA	Tricarboxylic Acid
TIC	Total Ion Chromatogram
TPTZ	2,4,6-tris (2-Pyridyl)-s-Triazine
TSP	Trimethylsilyl Propionic Acid
UCP	Uncoupling Protein
UV	Ultraviolet
WHO	World Health Organization

# CHAPTER ONE

## INTRODUCTION

### 1.1 BACKGROUND OF THE STUDY

Plant-based traditional medicine always stands as a golden mark to exemplify the outstanding phenomenon of symbiosis. Natural products from the medicinal plants have been the popular alternative for the treatment of various diseases and primary health care. Verma et al. (2008) stated that 80% of people in developing countries is still dependent on traditional herbal medicine derived from plants and animals for their primary and secondary health issues. Herbal medicines have been practiced since antiquity by traditional medicine practitioners. It has been continuing in practice until today because of its cultural beliefs in many parts of the world and promising biomedical properties. Furthermore, owing to rising medical treatment cost as well as the emergence of new diseases, prevailing focus on an idea of evidence-based medicine in recent decades have been greatly addressed (Narins, 2000). According to Kim et al. (2015), it is forecast that, by the year 2050, the total global herbal drug market will increase to US\$ 5trillion.

*Momordica charantia* is a popular medicinal plant of the Cucurbitaceae family that is widely available in local market. It is known as ‘peria katak’ in Malay and bitter melon or bitter gourd in English (Premila and Lisa, 2007). It also has been reported to possess antidiabetic, antimicrobial, antioxidant, antiviral and antitumor activities (Grover and Yadav, 2004; Wu and Ng, 2008). Numerous studies have been reported on antidiabetic properties of *M. charantia* fruit extract using various rat models since 1950’s (Raman and Lau, 1996; Basch et al., 2003; Ojewole et al.,

2006). However, previous studies only analyzed some targeted biomarkers such as glucose and insulin to evaluate the efficacy of this fruit. It causes a bias interpretation of the results since the metabolism in diabetes is very complex. Our knowledge is still limited to reveal all metabolite alterations responsible to cause diabetes. Thus, the best approach to evaluate the efficacy of the sample is to analyze all possible metabolites in biofluids using a new holistic approach known as metabolomics. Metabolites profile of an organism reflects significant information about its physiological status. Another advantage of using this approach is the possibility to identify new biomarkers causing a particular disease, and to reveal the mode of action of herbs in the treatment of this disease (Gabrielsson et al., 2006). Some examples of this specific work are the application of NMR-based metabolomics to evaluate antidiabetic activity of natural *Centella asiatica* (Maulidiani et al., 2016), *Phyllanthus niruri* (Mediani et al., 2016), *Andrographis paniculate* (Akthar et al., 2016), and green tea (Zhang et al., 2013).

In recent years, the major obstacle faced by the herbal industries is overlooked findings of many possibly bioactive natural compounds during drug discoveries based on bioassay guided fractionation approach. It is because of the fact that the single bioactive agent found to be present in low abundance in natural sources and biological effect could arise due to a synergistic action of multiple bioactive ingredients in a single source or from a multiple source in a particular formulation (Williamson, 2001). Currently, metabolomics approach has been practiced to overcome the bottlenecks in the identification of bioactive compounds in medicinal herbs (Wang et al., 2006). It can help to rationalize the therapeutic superiority of many plant extracts over single isolated constituent. It identifies and quantifies multiple targets in order to obtain an overview of all compound classes

and brings an important insight into the natural product by linking putative bioactivity with some compounds in a targeted plant (Fiehn, 2002; Newman and Cragg 2007).

Identification of antioxidants in *M. charantia* fruit is important since these compounds correlate with antidiabetic activity through suppression of glycation of proteins, inactivation of enzymes, and alteration in structural functions of collagen basement membrane of pancreatic  $\beta$ -cell (Nirmala et al., 2011). Some antioxidants have been identified in this fruit, but there is a complete lack of information from the existing literature on the correlation of these compounds with an antidiabetic activity. Moreover, the antioxidant activity of the fruit crude extract does not confirm precisely about the total number of compounds responsible for an antioxidant effect of the fruit crude extract since all the existing studies had been based on the antioxidant activities of the different individual compounds. It is a well-known fact that the bioactivity of an individual compound may differ when these compounds are within the complex matrix of the plant material. For example, it is quite common that the antioxidant activity of a sample can disappear when it is fractionated, phenomenon attributed to possible synergistic effects with other components of the sample (Kuhlisch et al., 2015). Thus, the reported antioxidant compounds may not be solely or individually responsible for the antioxidant activity of the whole fruit. One way of detecting all the compounds related to antioxidant activity is to use metabolomics approach (Verpoorte et al., 2009).

The analytical methods that are used in metabolomics are varied. No single analytical instrument is available up to date to detect all range of compounds with high sensitivity and resolution. Thus, the use of different analytical instruments is highly recommended to detect as much as possible bioactive compounds in a sample.